Enlivex to hold webinar on $400 million placement, RAIN treasury, and Allocetra RMAT tag

Enlivex Ltd. said its management will hold a live webinar on July 30, 2026 at 10:00 AM Eastern Time to provide investors with additional detail on the company's recently announced private placement, the status and strategy of its Rain treasury, and recent clinical progress for Allocetra.¹

The agenda covers three areas. On the placement, management plans to discuss the rationale for the transaction, the company's intended use of proceeds, and how the transaction fits within its long-term treasury strategy built around the Rain protocol.¹ On the treasury, the company will review the current status of its treasury portfolio and recent milestones and growth roadmap provided by the Rain Foundation.¹ On the clinical side, the webinar will address the ongoing Phase 2b trial in age-related knee osteoarthritis and the newly granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for Allocetra in symptomatic knee osteoarthritis in patients 64 and older.¹

The private placement itself, announced July 28, 2026, involves a securities purchase agreement with a single institutional investor for $400,000,000 of ordinary shares or equivalents, priced at $5.00 per share for U.S. dollar, USDT or USD Coin funding and $6.00 per share for funding in RAIN tokens, representing premiums of 17.4% and 40.8% respectively to the July 27, 2026 closing price.² The investor elected to fund the purchase using RAIN tokens, an election that can be changed before closing.² Enlivex also holds a right, exercisable at its discretion over 36 months after closing, to require the investor to purchase up to an additional $400,000,000 of shares on the same pricing terms.² Closing depends on shareholder approval under Nasdaq Listing Rules 5635(a) and 5635(b) and Section 274 of the Israeli Companies Law.²